Foresight Capital's model of investing across early, middle, and late stages from one fund provides a unique advantage. Their understanding of late-stage market needs and challenges directly informs and improves their selection process for early-stage companies, creating a powerful feedback loop that specialized VCs lack.

The "NewCo" model, where a new company is formed around assets licensed from an existing firm, is a key strategy for Western investors to access a deep well of innovation from Chinese companies like Heisco, which are largely unknown in the West but possess broad, innovative pipelines.

Forbion identified an arbitrage: promising biotech assets in China whose originators lacked global development expertise. Their strategy is to create new Western companies, in-license these assets, and install an experienced team to unlock their "rest of world" value, a model proven by a billion-dollar exit.

Rather than competing in crowded auctions, elite private equity firms pursue a differentiated "executive new build" strategy. They partner with proven operators to build new companies from scratch to address a market need, creating proprietary deals that other firms cannot access.

Top VCs are reviving the early, hands-on model of pioneers like Arthur Rock. Instead of just investing, firms are co-designing new labs from scratch, providing compute, capital, and commercial guidance. This "company creation" approach is viable again as capital is no longer the primary bottleneck for ambitious, frontier-tech ideas.

Contrary to the popular image of founders pitching VCs, Rohan Oza's firm, Kavu, operates on the principle that the best deals must be actively sought out. They employ a dedicated team for 'the hunt,' proactively sourcing promising brands and founders instead of relying on passive inbound deal flow.

Roivant's early success came from identifying and building companies around promising drug assets that were deemed non-strategic by large pharmaceutical firms. This approach capitalized on undervalued IP and focused execution, pre-dating the now-common trend of pharma spin-outs.

The acquisition of Oro highlights the success of the "NUCO" model, where Chinese biotechs like KeyMed spin out assets into new companies. These NUCOs are backed by Western VCs specifically to achieve global development and a lucrative exit, creating a repeatable pathway for Asian science to reach Western markets.

Venture capital is shifting towards creating new companies from multiple de-risked assets acquired from large pharma. Bain's $300M investment to build a company around five BMS assets, led by a proven CEO, exemplifies this strategy. It mirrors previous successes like SpringWorks and minimizes single-asset failure risk.